A de novo dominant-negative variant is associated with OTULIN-related autoinflammatory syndrome

一种新发显性负性变异与OTULIN相关自身炎症综合征有关

阅读:7
作者:Yukiko Takeda ,Masahiro Ueki ,Junpei Matsuhiro ,Erik Walinda ,Takayuki Tanaka ,Masafumi Yamada ,Hiroaki Fujita ,Shunichiro Takezaki ,Ichiro Kobayashi ,Sakura Tamaki ,Sanae Nagata ,Noriko Miyake ,Naomichi Matsumoto ,Mitsujiro Osawa ,Takahiro Yasumi ,Toshio Heike ,Fumiaki Ohtake ,Megumu K Saito ,Junya Toguchida ,Junko Takita ,Tadashi Ariga ,Kazuhiro Iwai

Abstract

OTULIN-related autoinflammatory syndrome (ORAS), a severe autoinflammatory disease, is caused by biallelic pathogenic variants of OTULIN, a linear ubiquitin-specific deubiquitinating enzyme. Loss of OTULIN attenuates linear ubiquitination by inhibiting the linear ubiquitin chain assembly complex (LUBAC). Here, we report a patient who harbors two rare heterozygous variants of OTULIN (p.P152L and p.R306Q). We demonstrated accumulation of linear ubiquitin chains upon TNF stimulation and augmented TNF-induced cell death in mesenchymal stem cells differentiated from patient-derived iPS cells, which confirms that the patient has ORAS. However, although the de novo p.R306Q variant exhibits attenuated deubiquitination activity without reducing the amount of OTULIN, the deubiquitination activity of the p.P152L variant inherited from the mother was equivalent to that of the wild-type. Patient-derived MSCs in which the p.P152L variant was replaced with wild-type also exhibited augmented TNF-induced cell death and accumulation of linear chains. The finding that ORAS can be caused by a dominant-negative p.R306Q variant of OTULIN furthers our understanding of disease pathogenesis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。